Pharmacokinetic Drug Interactions

A pharmacokinetic drug interaction occurs when one drug (the precipitant) changes how the body handles another drug (the object) — its absorption, distribution, metabolism, or excretion — so that the amount of the object drug reaching its site of action, and the duration it stays there, is altered. The drug's intrinsic action is unchanged; what changes is its concentration over time.

Definition

A pharmacokinetic drug interaction is an interaction in which a precipitant drug alters the absorption, distribution, metabolism, or excretion of an object drug, changing the object drug's concentration at its site of action without directly changing its pharmacological mechanism.

Scope

The topic covers the four classical loci of pharmacokinetic interaction — absorption, distribution, metabolism, and excretion — with particular weight on metabolic interactions mediated by drug-metabolising enzymes and on transporter-mediated interactions. It treats these as mechanistic and reference material, distinct from pharmacodynamic interactions (in which concentrations are unchanged) and without offering dosing or prescribing instruction.

Core questions

• Which step of absorption, distribution, metabolism, or excretion is being altered?
• Is the precipitant inhibiting or inducing a metabolising enzyme or transporter?
• How large and how clinically meaningful is the resulting change in the object drug's exposure?

Key concepts

• Object drug and precipitant drug
• Absorption interactions (chelation, pH change, motility)
• Distribution and plasma protein-binding displacement
• Metabolic inhibition and induction
• Cytochrome P450 enzymes
• Drug transporters (P-glycoprotein and others)
• Drug exposure (area under the concentration-time curve)

Mechanisms

At absorption, a precipitant can bind or chelate the object drug, change gastric pH, or alter gut motility, changing how much is absorbed. At distribution, displacement from plasma protein binding can transiently raise free drug concentration, though this is often clinically minor because clearance compensates. The most clinically important interactions are metabolic: a precipitant that inhibits a metabolising enzyme raises the object drug's concentration, while one that induces the enzyme lowers it, with cytochrome P450 enzymes mediating a large share of these effects (tanaka-1998). Excretion interactions act on renal tubular secretion and reabsorption or on biliary clearance. Membrane transporters such as P-glycoprotein govern uptake and efflux and are a further site at which one drug can change another's exposure, sometimes alongside an enzyme effect (itc-2010; durr-2000).

Clinical relevance

Pharmacokinetic interactions account for many clinically significant drug-drug interactions, including some involving over-the-counter products and herbal supplements that patients may not report (honig-1998; durr-2000). This entry explains the mechanisms by which exposure changes occur and supports the appraisal of interaction evidence; it is not prescribing, monitoring, or dosing guidance, which require current professional sources and individual assessment.

Evidence & guidelines

Characterising which enzymes and transporters handle a drug is a core part of modern drug development and regulatory evaluation, because it predicts where pharmacokinetic interactions will occur (itc-2010). Reviews of clinically important interactions emphasise the central role of cytochrome P450 metabolism (tanaka-1998). Decisions about specific combinations, dose adjustment, and monitoring belong to current clinical guidelines and are outside this reference entry.

History

The systematic, mechanism-based understanding of pharmacokinetic interactions grew through the later twentieth century as the cytochrome P450 enzyme family was characterised and as drug transporters were identified and linked to clinical exposure changes. The recognition that common non-prescription and herbal products can act as potent enzyme inducers or inhibitors — illustrated by St John's wort inducing CYP3A4 and P-glycoprotein — broadened the field beyond conventional prescription drugs (durr-2000; honig-1998).

Seminal works

• tanaka-1998
• itc-2010
• durr-2000

Frequently asked questions

How does a pharmacokinetic interaction differ from a pharmacodynamic one?

A pharmacokinetic interaction changes how much of a drug is present (its concentration) by altering absorption, distribution, metabolism, or excretion. A pharmacodynamic interaction leaves concentrations unchanged but alters the drug's effect because two drugs act on the same or opposing systems.

Why is metabolic inhibition often more dangerous than metabolic induction?

Inhibiting the enzyme that clears a drug can raise its concentration relatively quickly, increasing the risk of toxicity; induction lowers concentration and tends to develop more slowly as new enzyme is synthesised. Both can be clinically important, in opposite directions.